Please check your internet connection and try again.
# Sompraz HP (Pantoprazole)
## Overview
Sompraz HP is a combination product containing pantoprazole, an acid suppressor, and specific antibiotics for the eradication of *Helicobacter pylori* infection. Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion.
## Primary Indications
* Treatment of *Helicobacter pylori* infection in patients with peptic ulcer disease.
## Adult Dosing
The typical regimen involves:
* Pantoprazole 40 mg orally twice daily for 7 to 14 days.
* Amoxicillin 1000 mg orally twice daily for 7 to 14 days.
* Clarithromycin 500 mg orally twice daily for 7 to 14 days.
*Note: The specific duration and antibiotic components of the regimen may vary based on local resistance patterns and prescribing guidelines.*
## Pediatric Dosing
Specific pediatric dosing for Sompraz HP is not established. Dosing for individual components (pantoprazole, amoxicillin, clarithromycin) should be determined based on age, weight, and the specific indication, following appropriate pediatric guidelines.
## Dose Adjustments
* **Hepatic Impairment:** A maximum dose of 20 mg pantoprazole daily is recommended for patients with severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is typically needed for pantoprazole in renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole, amoxicillin, clarithromycin, or any component of the formulation.
* History of allergic reactions to penicillins, cephalosporins, or macrolides.
* Severe hepatic impairment (for pantoprazole component).
* Use in patients with a history of QT prolongation or ventricular arrhythmias (associated with clarithromycin).
* Concomitant use with specific drugs that interact with clarithromycin (e.g., colchicine, lovastatin, simvastatin).
## Adverse Effects
* **Common:** Diarrhea, headache, nausea, abdominal pain, dizziness, rash.
* **Serious:** *Clostridium difficile*-associated diarrhea, severe allergic reactions, *QT* interval prolongation, * Stevens-Johnson syndrome*, *toxic epidermal necrolysis*, *renal impairment* (particularly with clarithromycin). Long-term PPI use may be associated with an increased risk of *fractures*, *vitamin B12 deficiency*, and *hypomagnesemia*.
## Key Drug Interactions
* **Pantoprazole:** Can alter the absorption of drugs that require an acidic gastric environment (e.g., ketoconazole, itraconazole, iron salts, vitamin B12). May increase serum levels of methotrexate.
* **Clarithromycin:** Significant interactions with CYP3A4 substrates (e.g., carbamazepine, cisapride, cyclosporine, digoxin, disopyramide, ergot alkaloids, lovastatin, midazolam, pimozide, quinidine, ritonavir, simvastatin, tacrolimus, triazolam, valproic acid). May increase serum levels of other drugs, including warfarin and theophylline.
* **Amoxicillin:** May decrease the effectiveness of oral contraceptives.
## Monitoring
* Monitor for signs and symptoms of *H. pylori* eradication (e.g., symptom improvement, urea breath test, stool antigen test).
* Monitor for adverse effects, especially *diarrhea*, *rash*, and signs of hypersensitivity.
* Monitor electrolytes (especially magnesium) with prolonged PPI use.
* Monitor for signs of *QT* prolongation if risk factors are present with clarithromycin.
## Clinical Pearls
* Sompraz HP is a fixed-dose combination, and the duration of therapy is typically fixed (7 to 14 days).
* Compliance with the full course of therapy is crucial for successful *H. pylori* eradication.
* Patients should be advised to report any severe or persistent diarrhea immediately.
* Consider alternative *H. pylori* eradication regimens in patients with a history of macrolide allergy or penicillin allergy.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.
